These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 19052483

  • 1. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V, Hocht C, Mangano A, Niselman V, Mariño Hernández E, Cáceres Guido P, Mecikovsky D, Bellusci C, Bologna R, Sen L, Rubio MC, Bramuglia GF.
    Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
    [Abstract] [Full Text] [Related]

  • 2. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
    Wasmuth JC, Rodermann E, Voigt E, Vogel M, Lauenroth-Mai E, Jessen A, Burger D, Rockstroh JK.
    Eur J Med Res; 2007 Jul 26; 12(7):289-94. PubMed ID: 17933700
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).
    Wasmuth JC, la Porte CJ, Schneider K, Burger DM, Rockstroh JK.
    Antivir Ther; 2004 Apr 26; 9(2):213-20. PubMed ID: 15134183
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
    Rhame FS, Rawlins SL, Petruschke RA, Erb TA, Winchell GA, Wilson HM, Edelman JM, Abramson MA.
    Antimicrob Agents Chemother; 2004 Nov 26; 48(11):4200-8. PubMed ID: 15504842
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
    Hennessy M, Clarke S, Spiers JP, Mulcahy F, Kelleher D, Meadon E, Maher B, Bergin C, Khoo S, Tjia J, Hoggard P, Back D, Barry M.
    Antivir Ther; 2003 Jun 26; 8(3):191-8. PubMed ID: 12924535
    [Abstract] [Full Text] [Related]

  • 19. [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].
    Bani-Sadr F, Perré P, Peytavin G, Bernard L, Melchior JC, Perronne C, de Truchis P.
    Presse Med; 2001 Apr 21; 30(15):731-5. PubMed ID: 11360738
    [Abstract] [Full Text] [Related]

  • 20. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC, Lambertz I, Voigt E, Vogel M, Hoffmann C, Burger D, Rockstroh JK.
    Eur J Clin Pharmacol; 2007 Oct 21; 63(10):901-8. PubMed ID: 17690876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.